Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in:

11.08.2023 | Chronic Daily Headache (S-J Wang and S-P Chen, Section Editors)

Hemicrania Continua: An Update

verfasst von: Haidar M. Al-Khazali, Rune Häckert Christensen, Giorgio Lambru, David W. Dodick, Håkan Ashina

Erschienen in: Current Pain and Headache Reports | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Hemicrania Continua (HC) is a rare and disabling primary headache disorder that is characterized by persistent, unilateral headache with ipsilateral, cranial autonomic symptoms and restlessness or agitation. The diagnosis requires patients to experience an absolute response to therapeutic doses of indomethacin.

Recent Findings

HC is diagnosed in in about 1.8% of adult patients who were evaluated for headache in tertiary care services, albeit this estimate should be interpreted with caution. The most prevalent accompanying symptoms appear to be lacrimation, conjunctival injection and restlessness or agitation. However, the available literature is limited by methodologic issues, and the current diagnostic criteria lack clarity on what defines absolute response to indomethacin. More rigorous studies are thus needed to improve our understanding of HC which, in turn, will facilitate better disease management in clinical practice.

Summary

Here, we provide a comprehensive overview of HC, including its epidemiology, clinical presentation, diagnostic evaluation, and management.
Literatur
1.
• Diener HC, Tassorelli C, Dodick DW. Management of Trigeminal Autonomic Cephalalgias Including Chronic Cluster. JAMA Neurol. 2023;80:308. This reference provides an overview of TACs, including how to differentiate between HC and other differential diagnoses.CrossRef
2.
Hryvenko I, Cervantes-Chavarría AR, Law AS, Nixdorf DR. Hemicrania continua: Case series presenting in an orofacial pain clinic. Cephalalgia. 2018;38:1950–9.CrossRefPubMed
3.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
4.
• Al-Khazali HM, Al-Khazali S, Iljazi A, Christensen RH, Ashina S, Lipton RB, et al. Prevalence and clinical features of hemicrania continua in clinic-based studies: A systematic review and meta-analysis. Cephalalgia. 2023;43:033310242211313. This reference estimates the relative frequencies of hemicrania continua and its clinical features in among people who were evaluated for headache in a clinic-based setting.
5.
Wei DY, Goadsby PJ. Recent Advances and Updates in Trigeminal Autonomic Cephalalgias. Semin Neurol. 2022;42:474–8.CrossRefPubMed
6.
Peres MFP, Silberstein SD, Nahmias S, Shechter AL, Youssef I, Rozen TD, et al. Hemicrania continua is not that rare. Neurology. 2001;57:948–51.CrossRefPubMed
7.
8.
Prakash S, Rathore C, Rana K, Joshi H, Patel J, Rawat KS. A long-term prospective observational study in 31 patients with hemicrania continua. Cephalalgia Rep. 2019;2:251581631882469.CrossRef
9.
Prakash S, Rawat K. Hemicrania Continua: An Update. Neurol India. 2021;69:160.CrossRef
10.
Prakash S, Golwala P. A proposal for revision of hemicrania continua diagnostic criteria based on critical analysis of 62 patients. Cephalalgia. 2012;32:860–8.CrossRefPubMed
11.
Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain. 2010;133:1973–86.CrossRefPubMed
12.
13.
Ziegeler C, May A. Facial presentations of migraine, TACs, and other paroxysmal facial pain syndromes. Neurology. 2019;93:e1138–47.CrossRefPubMed
14.
May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet. 2005;366:843–55.
15.
Ashina M, Terwindt GM, Al-Karagholi MA-M, de Boer I, Lee MJ, Hay DL, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021;397:1496–504.
16.
Rasmussen BK, Jensen R, Olesen J. A Population-Based Analysis of the Diagnostic Criteria of the International Headache Society. Cephalalgia. 1991;11:129–34.CrossRefPubMed
17.
Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW, et al. Most bothersome symptom in persons with migraine: results from the migraine in america symptoms and treatment (MAST) Study. Headache: J Head Face Pain. 2020;60:416–29.
18.
Christensen CG, Techlo TR, Kogelman LJ, Wegner Thørner L, Nissen J, Sørensen E, et al. Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria. Cephalalgia. 2022;42:1160–71.CrossRefPubMed
19.
20.
Peng K-P, Fuh J-L, Yuan H-K, Shia B-C, Wang S-J. New daily persistent headache: Should migrainous features be incorporated? Cephalalgia. 2011;31:1561–9.CrossRefPubMed
21.
Rozen TD. New daily persistent headache (NDPH) triggered by a single Valsalva event: A case series. Cephalalgia. 2019;39:785–91.CrossRefPubMed
22.
Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache: J Head Face Pain. 2004;44:747–61.
23.
Marek S, Tervo-Clemmens B, Calabro FJ, Montez DF, Kay BP, Hatoum AS, et al. Publisher Correction: Reproducible brain-wide association studies require thousands of individuals. Nature. 2022;605:E11–E11.CrossRefPubMedPubMedCentral
24.
Baraldi C, Pellesi L, Guerzoni S, Cainazzo MM, Pini LA. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain. 2017;18:71.CrossRefPubMedPubMedCentral
25.
Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic Paroxysmal Hemicrania and Hemicrania Continua. Parenteral Indomethacin: The “Indotest.” Headache: J Head Face Pain. 1998;38:122–8.
26.
Pareja JA, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. interval between indomethacin administration and response. Headache: J Head Face Pain. 1996;36:20–3.
27.
Marmura M, Silberstein S, Gupta M. Hemicrania continua: who responds to Indomethacin? Cephalalgia. 2009;29:300–7.CrossRefPubMed
28.
Pareja J, Caminero A, Franco E, Casado J, Pascual J, del Río MS. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia. 2001;21:906–10.CrossRefPubMed
29.
Rozen TD. How effective is melatonin as a preventive treatment for hemicrania continua? a clinic-based study. Headache: J Head Face Pain. 2015;55:430–6.
30.
Peres MFP, Silberstein SD. Hemicrania continua responds to cyclooxygenase‐2 Inhibitors. Headache: J Head Face Pain. 2002;42:530–1.
31.
Miller S, Correia F, Lagrata S, Matharu MS. OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients. J Headache Pain. 2015;16:19.CrossRefPubMedPubMedCentral
32.
Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves. Funct Neurol. 1997;12:11–5.PubMed
33.
34.
Brighina F, Palermo A, Cosentino G, Fierro B. Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate. Headache: J Head Face Pain. 2007;47:441–3.
35.
Camarda C, Camarda R, Monastero R. Chronic paroxysmal hemicrania and hemicrania continua responding to topiramate: Two case reports. Clin Neurol Neurosurg. 2008;110:88–91.CrossRefPubMed
36.
37.
Prakash S, Husain M, Sureka DS, Shah NP, Shah ND. Is there need to search for alternatives to indomethacin for hemicrania continua? Case reports and a review. J Neurol Sci. 2009;277:187–90.CrossRefPubMed
38.
39.
Trimboli M, Al-Kaisy A, Andreou AP, Murphy M, Lambru G. Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: A real-world experience. Cephalalgia. 2018;38:1276–85.CrossRefPubMed
40.
Villar‐Martínez MD, Moreno‐Ajona D, Chan C, Goadsby PJ. Indomethacin‐responsive headaches—A narrative review. Headache: J Head Face Pain. 2021;61:700–14.
41.
Barbanti P, Fabbrini G, Pesare M, Vanacore N, Cerbo R. Unilateral cranial autonomic symptoms in migraine. Cephalalgia. 2002;22:256–9.CrossRefPubMed
42.
González-Quintanilla V, Pérez-Pereda S, Fontanillas N, Pascual J. First case of hemicrania continua responsive to galcanezumab. Neurol Sci. 2021;42:4775–6.CrossRefPubMed
Metadaten
Titel
Hemicrania Continua: An Update
verfasst von
Haidar M. Al-Khazali
Rune Häckert Christensen
Giorgio Lambru
David W. Dodick
Håkan Ashina
Publikationsdatum
11.08.2023
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 10/2023
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-023-01156-9

Weitere Artikel der Ausgabe 10/2023

The Role of Step Therapy in the Treatment of Migraine

  • Hot Topics in Pain and Headache (N Rosen, Section Editor)

Chest Wall and Abdominal Blocks for Thoracic and Abdominal Surgeries: A Review

  • Acute Pain Medicine (R Urman, Section Editor)

Ketamine for Chronic Pain and Mental Health: Regulations, Legalities, and the Growth of Infusion Clinics

  • Hot Topics in Pain and Headache (N Rosen, Section Editor)

The Emerging Role of Peripheral Nerve Stimulation in Postoperative Analgesia

  • Acute Pain Medicine (R Urman, Section Editor)

Cebranopadol for the Treatment of Chronic Pain

  • Chronic Pain Medicine (O Viswanath, Section Editor)

Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations

  • Episodic Migraine (S Parikh, Section Editor)

Neu im Fachgebiet AINS

Verschlechtert frühe Hyperoxie nach Reanimation die Prognose?

Kommt es sehr früh nach einer kardiopulmonalen Reanimation zu einem Zustand der Hyperoxie, ist dies bei Patienten nach einem Herzstillstand mit schlechteren funktionellen Ergebnissen assoziiert. Das zeigt eine Sekundäranalyse der TTM-2-Studie.

Antibiotika bei Bakteriämie: 7 versus 14 Tage

  • 21.01.2025
  • Sepsis
  • Nachrichten

Eine Bakteriämie lässt sich mit einer einwöchigen Antibiotikatherapie zumeist gut in den Griff bekommen: Die Sterberate ist nicht höher als unter zweiwöchiger Behandlung, zeigt eine Vergleichsstudie mit hospitalisierten Erkrankten. Allerdings muss die Therapie bei fast jedem Vierten verlängert werden.

Nasenstimulation lindert chronische Migräne

Wird die Naseninnenseite durch Vibrationen stimuliert, kann dies offenbar die Zahl der Migränetage von Menschen mit chronischer Migräne deutlich senken. Darauf deuten die Resultate einer randomisiert-kontrollierten deutsch-finnischen Untersuchung.

Nackenschmerzen nach Bandscheibenvorfall: Muskeltraining hilft!

Bei hartnäckigen Schmerzen aufgrund einer zervikalen Radikulopathie schlägt ein Team der Universität Istanbul vor, lokale Steroidinjektionen mit einem speziellen Trainingsprogramm zur Stabilisierung der Nackenmuskulatur zu kombinieren.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise